Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe Europe Other stock markets 08:53:27 2024-05-20 am EDT			5-day change	1st Jan Change
404.8 ^SEK	+3.25%		+4.02%	+21.70%

Apr. 24	Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest	DJ
Apr. 24	Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Increased number of shares and votes in XVIVO Perfusion AB (publ)

October 02, 2023 at 09:56 am EDT

As of September 29, 2023, the total number of shares and votes in XVIVO Perfusion AB (publ) is 31,499,470.

The number of shares and votes has changed as a result of the directed new issue of 1,600,000 shares that the company announced on September 13, 2023.

Contact:

Christoffer Rosenblad

Tel: +46 73 519 21 59

Email: christoffer.rosenblad@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO.

Latest news about Xvivo Perfusion AB

Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest	Apr. 24	DJ
Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024	Apr. 24
Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague	Apr. 11	CI
Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	Mar. 15	CI
Nordic Shares Moved Upward Thursday; Nokia Topped Leaders	Jan. 25	DJ
Transcript : Xvivo Perfusion AB, 2023 Earnings Call, Jan 25, 2024	Jan. 25
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25	CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 25	CI
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss	Jan. 17	DJ
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published	Nov. 03	CI
Transcript : Xvivo Perfusion AB, Q3 2023 Earnings Call, Oct 24, 2023	23-10-24
Xvivo Perfusion AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
Xvivo Perfusion AB Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial	23-10-23	CI
Xvivo Perfusion AB Announces Appointment of Members of Nomination Committee	23-09-29	CI
Xvivo Perfusion to Raise SEK440 Million from Directed Share Issue	23-09-14	MT
Xvivo Perfusion Gets USFDA Nod on Using Donated Hearts in Heart Preservation Clinical Trial	23-07-25	MT
US Food & Drug Administration Grants Xvivo Perfusion AB Approval to Include DCD Heartarts in IDE Clinical Trial	23-07-25	CI
Transcript : Xvivo Perfusion AB, Q2 2023 Earnings Call, Jul 13, 2023	23-07-13
Xvivo Perfusion Closes PrimECC Trial Amid Patient Recruitment Challenges	23-07-13	MT
Xvivo Perfusion AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-13	CI
Xvivo Perfusion AB Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated	23-07-12	CI
XVIVO Perfusion AB Enters into A Strategic Collaboration with MTJ Aviation to Strengthen Organ Procurement Services in the US	23-07-10	CI
Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology	23-05-23	CI
Patient Inclusion Completed in European Clinical Trial with XVIVO's Heart Preservation Technology	23-05-23	CI

Chart Xvivo Perfusion AB

Duration

Period

More charts

Company Profile

Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Companyâs product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-12 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Xvivo Perfusion AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

392 SEK

Average target price

408 SEK

Spread / Average Target

+4.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
XVIVO PERFUSION AB	+21.70%	1.15B
ABBOTT LABORATORIES	-5.43%	181B
MEDTRONIC PLC	+4.30%	114B
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B
DEXCOM, INC.	+5.86%	52.24B
CENCORA, INC.	+8.15%	44.3B
HOYA CORPORATION	+6.67%	42.73B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B
TERUMO CORPORATION	+20.03%	26.02B
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B

Other Medical Equipment, Supplies & Distribution